• Dry Cracked Skin
  • Impetigo
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Revolutionizing Atopic Dermatitis Recap: Day 3


Catch up on coverage from the third day of Revolutionizing Atopic Dermatitis.


The Science of Atopic Dermatitis With Anna De Benedetto, MD

De Benedetto shares her expertise on new discoveries in the science of atopic dermatitis at RAD 2023.

No Differences in Severity or Treatment Among Racially Diverse Eczema Patients

In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.

Boxed Warnings Should Not Create a Fear of Using All JAK Inhibitors for AD

Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.

Lebrikizumab Efficacious in Clearing Hand, Facial Atopic Dermatitis

In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.

Crisaborole Ointment Leads to Significant, Consistent Improvements in AD

In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.

New Drugs in 2023, Patient Satisfaction, and RAD Takeaways With Melinda Gooderham, MSc, MD, FRCPC

Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.

Late-Breaking Data: Dupilumab Significantly Improves Signs, Symptoms, and QoL in Patients With Hand & Foot Dermatitis

Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.

Abrocitinib Has Acceptable Long-Term Safety Profile in Adolescents with AD

Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.

Keep up to date with the latest in coverage from the conference and subscribe to Dermatology Times to receive daily email updates.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.